Effectiveness of Parkinson´s Disease Multimodal Complex Treatment considering treatment duration and patient satisfactio

Not Applicable

• Conditions: PARKINSONMultimodal Complex TreatmentNon-Adherence; G20.0; G20.1; G20.2; G20.9

• Registration Number: DRKS00025225
• Lead Sponsor: Department of Neurology, Jena University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-30
• Study Completion: 2023-09-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patients with idiopathic Parkinson´s disease (according to the MDS-criteria) who were admitted to the Parkinson´s disease multimodal complex treatment.

Exclusion Criteria

inability to provide informed consent to participate in the study; acute psychotic symptoms; inability to complete a questionnaire, severe dementia.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in motor function assessed with the MDS-UPDRS II in the medication ON-state six months after discharge from Parkinson´s disease multimodal complex treatment (OPS 8-97d.0, OPS 8-97d.1).

Secondary Outcome Measures

Name	Time	Method
Change in health-related quality of life (PDQ-8) after six months; impact of the treatment duration on changes in MDS-UPDRS II and PDQ-8; patient satisfaction or dissatisfaction with the treatment